| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveitis | 41 | 2025 | 53 | 7.860 |
Why?
|
| Cytomegalovirus Retinitis | 44 | 2026 | 47 | 5.160 |
Why?
|
| AIDS-Related Opportunistic Infections | 42 | 2026 | 49 | 4.240 |
Why?
|
| Toxoplasmosis, Ocular | 30 | 2015 | 30 | 3.960 |
Why?
|
| Retinal Diseases | 40 | 2026 | 48 | 3.880 |
Why?
|
| Acquired Immunodeficiency Syndrome | 42 | 2019 | 65 | 3.720 |
Why?
|
| Humans | 253 | 2026 | 6794 | 3.670 |
Why?
|
| Chorioretinitis | 23 | 2017 | 23 | 3.540 |
Why?
|
| Uveitis, Anterior | 15 | 2022 | 16 | 3.190 |
Why?
|
| Adult | 141 | 2026 | 2113 | 2.670 |
Why?
|
| Male | 156 | 2026 | 3671 | 2.590 |
Why?
|
| Female | 138 | 2026 | 4060 | 2.430 |
Why?
|
| Eye Infections, Viral | 17 | 2026 | 18 | 2.060 |
Why?
|
| Antiviral Agents | 36 | 2026 | 53 | 1.950 |
Why?
|
| Middle Aged | 111 | 2026 | 2108 | 1.930 |
Why?
|
| Visual Acuity | 59 | 2026 | 123 | 1.840 |
Why?
|
| Ganciclovir | 23 | 2020 | 24 | 1.750 |
Why?
|
| Cytomegalovirus Infections | 27 | 2011 | 31 | 1.700 |
Why?
|
| Tomography, Optical Coherence | 12 | 2026 | 48 | 1.660 |
Why?
|
| Arthritis, Juvenile | 8 | 2022 | 9 | 1.630 |
Why?
|
| Eye Diseases | 21 | 2021 | 34 | 1.540 |
Why?
|
| Adolescent | 51 | 2022 | 869 | 1.450 |
Why?
|
| Child | 40 | 2022 | 524 | 1.440 |
Why?
|
| Follow-Up Studies | 29 | 2026 | 268 | 1.250 |
Why?
|
| HIV Infections | 24 | 2014 | 432 | 1.250 |
Why?
|
| Prospective Studies | 27 | 2026 | 331 | 1.250 |
Why?
|
| Choroid Diseases | 10 | 2008 | 11 | 1.230 |
Why?
|
| Ophthalmology | 15 | 2020 | 39 | 1.220 |
Why?
|
| Retina | 13 | 2019 | 29 | 1.220 |
Why?
|
| Glucocorticoids | 15 | 2026 | 65 | 1.210 |
Why?
|
| Ebolavirus | 2 | 2020 | 2 | 1.210 |
Why?
|
| Hemorrhagic Fever, Ebola | 2 | 2020 | 3 | 1.210 |
Why?
|
| Eye Infections, Bacterial | 11 | 2016 | 15 | 1.200 |
Why?
|
| Cataract | 5 | 2023 | 20 | 1.150 |
Why?
|
| Vision Disorders | 15 | 2015 | 52 | 1.140 |
Why?
|
| Disease Outbreaks | 6 | 2016 | 12 | 1.130 |
Why?
|
| Retinitis | 15 | 2010 | 16 | 1.110 |
Why?
|
| Retrospective Studies | 42 | 2026 | 681 | 1.100 |
Why?
|
| Cross-Sectional Studies | 24 | 2022 | 506 | 1.090 |
Why?
|
| Quality of Life | 8 | 2022 | 184 | 1.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 15 | 2020 | 39 | 1.040 |
Why?
|
| Contrast Sensitivity | 10 | 2015 | 13 | 0.990 |
Why?
|
| Aged | 47 | 2026 | 1539 | 0.970 |
Why?
|
| Keratitis | 11 | 2016 | 12 | 0.950 |
Why?
|
| Vitreous Body | 13 | 2016 | 14 | 0.950 |
Why?
|
| Toxoplasma | 11 | 2016 | 11 | 0.910 |
Why?
|
| Risk Factors | 35 | 2021 | 767 | 0.870 |
Why?
|
| Retinal Detachment | 7 | 2026 | 9 | 0.810 |
Why?
|
| Uveitis, Posterior | 7 | 2017 | 8 | 0.810 |
Why?
|
| Immunosuppressive Agents | 12 | 2025 | 31 | 0.790 |
Why?
|
| HIV | 3 | 2019 | 16 | 0.790 |
Why?
|
| CD4-Positive T-Lymphocytes | 16 | 2018 | 38 | 0.760 |
Why?
|
| Eye Abnormalities | 1 | 2022 | 3 | 0.750 |
Why?
|
| Anti-Bacterial Agents | 9 | 2016 | 73 | 0.740 |
Why?
|
| Aqueous Humor | 8 | 2007 | 13 | 0.730 |
Why?
|
| Toxoplasmosis | 3 | 2016 | 3 | 0.730 |
Why?
|
| CD4 Lymphocyte Count | 28 | 2020 | 45 | 0.720 |
Why?
|
| Antiprotozoal Agents | 8 | 2015 | 8 | 0.700 |
Why?
|
| Synovitis | 2 | 2018 | 3 | 0.690 |
Why?
|
| Students, Medical | 1 | 2021 | 39 | 0.690 |
Why?
|
| Child, Preschool | 16 | 2022 | 258 | 0.680 |
Why?
|
| Lens, Crystalline | 3 | 2016 | 5 | 0.670 |
Why?
|
| Fundus Oculi | 16 | 2021 | 20 | 0.660 |
Why?
|
| S100A12 Protein | 1 | 2020 | 1 | 0.650 |
Why?
|
| Anterior Chamber | 5 | 2022 | 11 | 0.650 |
Why?
|
| Tears | 1 | 2020 | 3 | 0.650 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2020 | 9 | 0.650 |
Why?
|
| Interleukin-8 | 1 | 2020 | 10 | 0.650 |
Why?
|
| International Classification of Diseases | 2 | 2018 | 8 | 0.640 |
Why?
|
| Vitrectomy | 6 | 2016 | 6 | 0.640 |
Why?
|
| Herpes Zoster Ophthalmicus | 10 | 2026 | 12 | 0.610 |
Why?
|
| Uveomeningoencephalitic Syndrome | 6 | 2008 | 7 | 0.600 |
Why?
|
| Biomarkers | 2 | 2020 | 214 | 0.600 |
Why?
|
| Antirheumatic Agents | 4 | 2026 | 7 | 0.580 |
Why?
|
| Visual Fields | 11 | 2026 | 70 | 0.570 |
Why?
|
| Retinal Vessels | 6 | 2011 | 12 | 0.560 |
Why?
|
| Drug Therapy, Combination | 19 | 2026 | 84 | 0.550 |
Why?
|
| Fluorescein Angiography | 9 | 2019 | 10 | 0.550 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 35 | 0.550 |
Why?
|
| Optical Imaging | 1 | 2017 | 2 | 0.530 |
Why?
|
| Parents | 1 | 2018 | 42 | 0.530 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2017 | 8 | 0.530 |
Why?
|
| Eye Proteins | 4 | 2020 | 10 | 0.530 |
Why?
|
| Stress, Psychological | 1 | 2018 | 60 | 0.520 |
Why?
|
| Anti-HIV Agents | 8 | 2013 | 102 | 0.510 |
Why?
|
| Choroid | 2 | 2016 | 4 | 0.510 |
Why?
|
| Povidone-Iodine | 1 | 2016 | 2 | 0.510 |
Why?
|
| HLA-DQ Antigens | 3 | 2004 | 3 | 0.500 |
Why?
|
| Image Enhancement | 1 | 2016 | 6 | 0.500 |
Why?
|
| HLA-DR Antigens | 3 | 2008 | 6 | 0.490 |
Why?
|
| Acyclovir | 13 | 2026 | 13 | 0.490 |
Why?
|
| Eye | 5 | 2020 | 14 | 0.470 |
Why?
|
| Prevalence | 14 | 2021 | 259 | 0.450 |
Why?
|
| Recurrence | 16 | 2026 | 55 | 0.450 |
Why?
|
| United States | 13 | 2021 | 1019 | 0.430 |
Why?
|
| Treatment Outcome | 15 | 2025 | 500 | 0.430 |
Why?
|
| Aged, 80 and over | 18 | 2020 | 497 | 0.420 |
Why?
|
| Nephritis, Interstitial | 3 | 2003 | 6 | 0.420 |
Why?
|
| Surveys and Questionnaires | 10 | 2022 | 280 | 0.410 |
Why?
|
| HLA-A Antigens | 4 | 2008 | 5 | 0.410 |
Why?
|
| Methotrexate | 4 | 2025 | 11 | 0.410 |
Why?
|
| Ophthalmoscopy | 5 | 2021 | 15 | 0.400 |
Why?
|
| Cohort Studies | 10 | 2023 | 285 | 0.400 |
Why?
|
| Lenses, Intraocular | 4 | 1999 | 6 | 0.400 |
Why?
|
| Time Factors | 10 | 2020 | 321 | 0.390 |
Why?
|
| Young Adult | 13 | 2026 | 567 | 0.390 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 6 | 2001 | 6 | 0.380 |
Why?
|
| Chronic Disease | 10 | 2018 | 167 | 0.380 |
Why?
|
| Color Vision Defects | 4 | 2012 | 4 | 0.370 |
Why?
|
| Endophthalmitis | 5 | 2000 | 10 | 0.370 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 4 | 2006 | 11 | 0.370 |
Why?
|
| Lens Implantation, Intraocular | 4 | 2010 | 8 | 0.370 |
Why?
|
| Incidence | 13 | 2021 | 197 | 0.360 |
Why?
|
| Pyrimethamine | 4 | 2015 | 4 | 0.350 |
Why?
|
| Sulfadiazine | 4 | 2015 | 4 | 0.350 |
Why?
|
| Fluocinolone Acetonide | 3 | 2017 | 3 | 0.340 |
Why?
|
| Cornea | 9 | 2012 | 13 | 0.330 |
Why?
|
| Perceptual Disorders | 1 | 2010 | 1 | 0.320 |
Why?
|
| Phacoemulsification | 3 | 2002 | 7 | 0.320 |
Why?
|
| RNA, Viral | 6 | 2019 | 20 | 0.320 |
Why?
|
| Early Diagnosis | 2 | 2021 | 26 | 0.320 |
Why?
|
| Eye Infections, Fungal | 5 | 2012 | 8 | 0.320 |
Why?
|
| Foscarnet | 8 | 2000 | 8 | 0.310 |
Why?
|
| Cytomegalovirus | 6 | 2005 | 7 | 0.310 |
Why?
|
| Survivors | 3 | 2020 | 15 | 0.310 |
Why?
|
| HIV-1 | 6 | 2015 | 36 | 0.310 |
Why?
|
| Reproducibility of Results | 5 | 2022 | 112 | 0.300 |
Why?
|
| Teaching Materials | 1 | 2008 | 3 | 0.290 |
Why?
|
| Antibodies, Protozoan | 7 | 2015 | 8 | 0.290 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2005 | 4 | 0.280 |
Why?
|
| Administration, Oral | 10 | 2026 | 54 | 0.280 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 58 | 0.280 |
Why?
|
| Arthritis | 2 | 2018 | 5 | 0.280 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 5 | 2001 | 6 | 0.280 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 118 | 0.280 |
Why?
|
| Streptococcal Infections | 2 | 1999 | 3 | 0.280 |
Why?
|
| Antimetabolites | 2 | 2025 | 6 | 0.280 |
Why?
|
| Visual Field Tests | 6 | 2017 | 32 | 0.280 |
Why?
|
| Prednisone | 4 | 2025 | 7 | 0.280 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2020 | 35 | 0.280 |
Why?
|
| Prednisolone | 3 | 2015 | 3 | 0.270 |
Why?
|
| Drug Implants | 9 | 2017 | 16 | 0.270 |
Why?
|
| Optic Nerve Diseases | 3 | 2021 | 31 | 0.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2025 | 48 | 0.270 |
Why?
|
| Animals | 21 | 2016 | 1875 | 0.260 |
Why?
|
| Longitudinal Studies | 9 | 2015 | 140 | 0.260 |
Why?
|
| Anterior Eye Segment | 6 | 2007 | 9 | 0.260 |
Why?
|
| Azathioprine | 2 | 2025 | 3 | 0.260 |
Why?
|
| Laser Coagulation | 2 | 2026 | 6 | 0.260 |
Why?
|
| Immune System | 4 | 2000 | 14 | 0.250 |
Why?
|
| Melanoma | 5 | 2021 | 14 | 0.250 |
Why?
|
| Uveitis, Intermediate | 2 | 2017 | 2 | 0.250 |
Why?
|
| Corneal Stroma | 2 | 2026 | 3 | 0.250 |
Why?
|
| Pars Planitis | 1 | 2006 | 1 | 0.240 |
Why?
|
| Ischemia | 2 | 2006 | 7 | 0.240 |
Why?
|
| Zidovudine | 6 | 2013 | 8 | 0.240 |
Why?
|
| Hydroxychloroquine | 1 | 2026 | 7 | 0.240 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2005 | 49 | 0.240 |
Why?
|
| Keratitis, Dendritic | 6 | 2009 | 6 | 0.230 |
Why?
|
| Infant | 6 | 2015 | 187 | 0.230 |
Why?
|
| Glaucoma | 4 | 2014 | 103 | 0.230 |
Why?
|
| Ciliary Body | 3 | 1999 | 10 | 0.220 |
Why?
|
| Cataract Extraction | 3 | 2016 | 16 | 0.220 |
Why?
|
| Postoperative Complications | 9 | 2020 | 109 | 0.210 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 8 | 0.210 |
Why?
|
| Diagnosis, Differential | 5 | 2019 | 79 | 0.210 |
Why?
|
| Telemedicine | 2 | 2015 | 43 | 0.210 |
Why?
|
| Mycobacterium chelonae | 2 | 2001 | 3 | 0.210 |
Why?
|
| Uveal Neoplasms | 2 | 2021 | 3 | 0.200 |
Why?
|
| Global Health | 3 | 2014 | 54 | 0.200 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2023 | 8 | 0.200 |
Why?
|
| Clinical Competence | 2 | 2021 | 51 | 0.200 |
Why?
|
| Thailand | 7 | 2018 | 9 | 0.200 |
Why?
|
| Toxoplasmosis, Animal | 2 | 2016 | 2 | 0.190 |
Why?
|
| Eye Infections | 2 | 1992 | 2 | 0.190 |
Why?
|
| Herpes Zoster | 3 | 1992 | 3 | 0.190 |
Why?
|
| Syndrome | 6 | 2003 | 32 | 0.190 |
Why?
|
| Administration, Topical | 8 | 2016 | 20 | 0.190 |
Why?
|
| Intraocular Pressure | 8 | 2016 | 127 | 0.190 |
Why?
|
| Clinical Trials as Topic | 4 | 2015 | 54 | 0.180 |
Why?
|
| Disease Progression | 10 | 2018 | 170 | 0.180 |
Why?
|
| Electronic Health Records | 2 | 2020 | 34 | 0.180 |
Why?
|
| Neoplasms | 1 | 2023 | 92 | 0.180 |
Why?
|
| Registries | 2 | 2020 | 63 | 0.180 |
Why?
|
| Multimodal Imaging | 2 | 2019 | 5 | 0.180 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2001 | 2 | 0.180 |
Why?
|
| Leukocytes | 1 | 2001 | 9 | 0.180 |
Why?
|
| Teaching | 1 | 2021 | 13 | 0.180 |
Why?
|
| Gene Frequency | 4 | 2008 | 12 | 0.180 |
Why?
|
| Age Distribution | 3 | 2009 | 45 | 0.180 |
Why?
|
| Population Surveillance | 1 | 2021 | 30 | 0.180 |
Why?
|
| Hereditary Autoinflammatory Diseases | 2 | 2018 | 2 | 0.170 |
Why?
|
| Sarcoidosis | 2 | 2018 | 6 | 0.170 |
Why?
|
| Pregnancy | 5 | 2014 | 599 | 0.170 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2001 | 1 | 0.170 |
Why?
|
| Anti-Retroviral Agents | 4 | 2020 | 28 | 0.170 |
Why?
|
| DNA, Viral | 3 | 2009 | 10 | 0.170 |
Why?
|
| Retinal Hemorrhage | 3 | 2006 | 3 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 9 | 0.170 |
Why?
|
| Brazil | 7 | 2015 | 15 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 19 | 0.170 |
Why?
|
| Ipilimumab | 1 | 2020 | 2 | 0.170 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 3 | 0.170 |
Why?
|
| Delayed Diagnosis | 2 | 2018 | 5 | 0.170 |
Why?
|
| Immune Tolerance | 3 | 1990 | 8 | 0.170 |
Why?
|
| Immunotherapy | 1 | 2020 | 16 | 0.170 |
Why?
|
| Photography | 4 | 2014 | 26 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 26 | 0.170 |
Why?
|
| Granuloma | 3 | 2018 | 6 | 0.160 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 20 | 0.160 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 5 | 0.160 |
Why?
|
| Serologic Tests | 1 | 2000 | 3 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 19 | 0.160 |
Why?
|
| Infliximab | 4 | 2025 | 5 | 0.160 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2016 | 5 | 0.160 |
Why?
|
| Organophosphonates | 5 | 2006 | 6 | 0.160 |
Why?
|
| Capsulorhexis | 1 | 1999 | 1 | 0.150 |
Why?
|
| Sickness Impact Profile | 4 | 2017 | 10 | 0.150 |
Why?
|
| Suture Techniques | 1 | 1999 | 4 | 0.150 |
Why?
|
| Color Vision | 2 | 2017 | 2 | 0.150 |
Why?
|
| California | 7 | 2008 | 230 | 0.150 |
Why?
|
| Viremia | 2 | 1999 | 8 | 0.150 |
Why?
|
| Rheumatology | 1 | 2019 | 1 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 155 | 0.150 |
Why?
|
| Respiratory Tract Infections | 2 | 2011 | 11 | 0.150 |
Why?
|
| Mass Screening | 3 | 2019 | 116 | 0.150 |
Why?
|
| Biological Products | 1 | 2019 | 6 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 87 | 0.150 |
Why?
|
| Pharyngitis | 1 | 1999 | 1 | 0.150 |
Why?
|
| Streptococcus pyogenes | 1 | 1999 | 2 | 0.150 |
Why?
|
| Infusions, Intravenous | 4 | 1998 | 22 | 0.150 |
Why?
|
| Corneal Ulcer | 4 | 2012 | 7 | 0.150 |
Why?
|
| Adalimumab | 3 | 2025 | 4 | 0.150 |
Why?
|
| Computer Systems | 1 | 2018 | 6 | 0.150 |
Why?
|
| Encephalitis | 2 | 2016 | 6 | 0.140 |
Why?
|
| Age Factors | 3 | 2009 | 193 | 0.140 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 127 | 0.140 |
Why?
|
| Receptors, KIR | 2 | 2008 | 2 | 0.140 |
Why?
|
| Corneal Diseases | 3 | 2010 | 9 | 0.140 |
Why?
|
| Blindness | 2 | 2014 | 11 | 0.140 |
Why?
|
| Brain | 2 | 2016 | 94 | 0.140 |
Why?
|
| Case-Control Studies | 4 | 2014 | 108 | 0.130 |
Why?
|
| Macular Edema | 2 | 2015 | 9 | 0.130 |
Why?
|
| History, 20th Century | 3 | 2008 | 13 | 0.130 |
Why?
|
| Panuveitis | 1 | 2017 | 3 | 0.130 |
Why?
|
| Terminology as Topic | 2 | 2001 | 15 | 0.130 |
Why?
|
| Mutation | 1 | 2018 | 97 | 0.130 |
Why?
|
| Herpesvirus 3, Human | 4 | 2009 | 4 | 0.130 |
Why?
|
| Autoantibodies | 3 | 2012 | 12 | 0.130 |
Why?
|
| Cytosine | 5 | 2006 | 7 | 0.130 |
Why?
|
| Seroepidemiologic Studies | 4 | 2015 | 10 | 0.130 |
Why?
|
| Datasets as Topic | 1 | 2016 | 5 | 0.130 |
Why?
|
| Single-Blind Method | 1 | 2016 | 13 | 0.130 |
Why?
|
| Eye Injuries | 3 | 1998 | 4 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2016 | 20 | 0.130 |
Why?
|
| Psoriasis | 1 | 2016 | 4 | 0.130 |
Why?
|
| Corneal Endothelial Cell Loss | 1 | 2016 | 1 | 0.120 |
Why?
|
| Endothelium, Corneal | 1 | 2016 | 2 | 0.120 |
Why?
|
| Oocysts | 1 | 2016 | 1 | 0.120 |
Why?
|
| Staphylococcal Infections | 1 | 1996 | 16 | 0.120 |
Why?
|
| Dust | 1 | 2016 | 1 | 0.120 |
Why?
|
| Georgia | 1 | 2016 | 5 | 0.120 |
Why?
|
| Health Status | 2 | 2017 | 83 | 0.120 |
Why?
|
| Sex Distribution | 2 | 2009 | 44 | 0.120 |
Why?
|
| Orthodontic Appliances, Removable | 2 | 1986 | 2 | 0.120 |
Why?
|
| Genotype | 4 | 2016 | 28 | 0.120 |
Why?
|
| Triamcinolone Acetonide | 1 | 1995 | 2 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1996 | 28 | 0.120 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 98 | 0.110 |
Why?
|
| Photometry | 3 | 2005 | 3 | 0.110 |
Why?
|
| Organophosphorus Compounds | 4 | 1999 | 5 | 0.110 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2015 | 11 | 0.110 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 8 | 0.110 |
Why?
|
| Choroiditis | 2 | 1999 | 3 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 145 | 0.110 |
Why?
|
| Allied Health Personnel | 1 | 2014 | 1 | 0.110 |
Why?
|
| Age of Onset | 2 | 2007 | 16 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 4 | 2010 | 43 | 0.110 |
Why?
|
| Corneal Transplantation | 4 | 1999 | 7 | 0.110 |
Why?
|
| Mycophenolic Acid | 2 | 2025 | 7 | 0.110 |
Why?
|
| HLA-DR4 Antigen | 2 | 1995 | 2 | 0.110 |
Why?
|
| Silicone Oils | 3 | 2002 | 4 | 0.110 |
Why?
|
| Injections, Intravenous | 5 | 2006 | 19 | 0.110 |
Why?
|
| Trachoma | 1 | 2014 | 1 | 0.110 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2014 | 1 | 0.100 |
Why?
|
| HLA-DRB1 Chains | 2 | 2004 | 3 | 0.100 |
Why?
|
| HLA-DQ beta-Chains | 2 | 2004 | 3 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2010 | 169 | 0.100 |
Why?
|
| Tuberculosis, Ocular | 1 | 1993 | 1 | 0.100 |
Why?
|
| DNA | 2 | 2004 | 39 | 0.100 |
Why?
|
| Macular Degeneration | 1 | 2014 | 20 | 0.100 |
Why?
|
| Immunoglobulin G | 5 | 2014 | 19 | 0.100 |
Why?
|
| Keratotomy, Radial | 1 | 1993 | 1 | 0.100 |
Why?
|
| Astigmatism | 1 | 1993 | 3 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 1993 | 11 | 0.100 |
Why?
|
| Necrosis | 5 | 1999 | 30 | 0.100 |
Why?
|
| Cause of Death | 2 | 2011 | 82 | 0.100 |
Why?
|
| Opportunistic Infections | 5 | 1991 | 8 | 0.100 |
Why?
|
| Anti-Infective Agents | 3 | 2011 | 9 | 0.100 |
Why?
|
| Diabetic Retinopathy | 1 | 2014 | 52 | 0.100 |
Why?
|
| Corneal Dystrophies, Hereditary | 1 | 2013 | 2 | 0.100 |
Why?
|
| Didanosine | 1 | 2013 | 2 | 0.100 |
Why?
|
| Blepharoptosis | 1 | 2012 | 1 | 0.100 |
Why?
|
| Ophthalmoplegia, Chronic Progressive External | 1 | 2012 | 1 | 0.100 |
Why?
|
| Graft Rejection | 2 | 2010 | 26 | 0.100 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1992 | 17 | 0.090 |
Why?
|
| Valine | 2 | 2026 | 4 | 0.090 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 1992 | 9 | 0.090 |
Why?
|
| Axons | 1 | 2012 | 3 | 0.090 |
Why?
|
| Retinal Ganglion Cells | 1 | 2012 | 20 | 0.090 |
Why?
|
| Clarithromycin | 3 | 2004 | 7 | 0.090 |
Why?
|
| Retinal Artery | 1 | 2011 | 2 | 0.090 |
Why?
|
| Retinal Vein | 1 | 2011 | 3 | 0.090 |
Why?
|
| Pneumocystis Infections | 1 | 1991 | 1 | 0.090 |
Why?
|
| Fluoroquinolones | 1 | 2011 | 2 | 0.090 |
Why?
|
| Remote Consultation | 1 | 2011 | 7 | 0.090 |
Why?
|
| Amebiasis | 2 | 1990 | 2 | 0.090 |
Why?
|
| False Positive Reactions | 2 | 2014 | 13 | 0.090 |
Why?
|
| Databases, Factual | 3 | 2021 | 81 | 0.090 |
Why?
|
| Neutrophils | 2 | 2002 | 14 | 0.090 |
Why?
|
| History, 21st Century | 2 | 2008 | 8 | 0.090 |
Why?
|
| Hospitalization | 1 | 1992 | 128 | 0.090 |
Why?
|
| Color Perception Tests | 2 | 2012 | 2 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2008 | 63 | 0.090 |
Why?
|
| HIV Seropositivity | 4 | 2012 | 25 | 0.090 |
Why?
|
| Inflammation | 3 | 2008 | 143 | 0.080 |
Why?
|
| Publishing | 2 | 2002 | 11 | 0.080 |
Why?
|
| Electroretinography | 2 | 2026 | 2 | 0.080 |
Why?
|
| Internet | 2 | 2002 | 25 | 0.080 |
Why?
|
| Eye Neoplasms | 5 | 1989 | 5 | 0.080 |
Why?
|
| Water Microbiology | 1 | 2010 | 2 | 0.080 |
Why?
|
| Immunoglobulin M | 3 | 2015 | 6 | 0.080 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2010 | 6 | 0.080 |
Why?
|
| Immunocompetence | 1 | 2010 | 1 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2015 | 199 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2026 | 101 | 0.080 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2010 | 27 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2001 | 89 | 0.080 |
Why?
|
| Iris | 2 | 2006 | 5 | 0.080 |
Why?
|
| Injections | 4 | 2006 | 20 | 0.080 |
Why?
|
| Health Surveys | 2 | 2012 | 75 | 0.080 |
Why?
|
| Sarcoma, Kaposi | 6 | 1989 | 8 | 0.080 |
Why?
|
| Conjunctiva | 6 | 2007 | 9 | 0.080 |
Why?
|
| India | 1 | 2010 | 13 | 0.080 |
Why?
|
| Erythrocyte Aggregation | 2 | 2006 | 2 | 0.080 |
Why?
|
| Erythrocyte Deformability | 2 | 2006 | 2 | 0.080 |
Why?
|
| Virus Activation | 2 | 2000 | 3 | 0.080 |
Why?
|
| Conjunctival Diseases | 4 | 2005 | 5 | 0.080 |
Why?
|
| Portraits as Topic | 1 | 2008 | 1 | 0.070 |
Why?
|
| Crystallins | 1 | 2008 | 1 | 0.070 |
Why?
|
| Autoantigens | 1 | 2008 | 2 | 0.070 |
Why?
|
| Indians, North American | 1 | 2008 | 5 | 0.070 |
Why?
|
| Autoimmunity | 1 | 2008 | 3 | 0.070 |
Why?
|
| Intravitreal Injections | 2 | 2020 | 6 | 0.070 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 35 | 0.070 |
Why?
|
| Lasers | 2 | 2005 | 11 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 172 | 0.070 |
Why?
|
| Macula Lutea | 1 | 2007 | 6 | 0.070 |
Why?
|
| Angiography | 2 | 2018 | 15 | 0.070 |
Why?
|
| Water | 2 | 2015 | 13 | 0.070 |
Why?
|
| Debridement | 1 | 1987 | 5 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 120 | 0.070 |
Why?
|
| Urban Population | 1 | 2008 | 85 | 0.070 |
Why?
|
| Coccidioidomycosis | 1 | 2007 | 3 | 0.070 |
Why?
|
| Mice | 4 | 2010 | 746 | 0.070 |
Why?
|
| Eyelid Diseases | 2 | 2003 | 2 | 0.060 |
Why?
|
| Cryoglobulinemia | 1 | 2006 | 1 | 0.060 |
Why?
|
| Antihypertensive Agents | 2 | 2010 | 56 | 0.060 |
Why?
|
| Los Angeles | 1 | 2008 | 321 | 0.060 |
Why?
|
| Color Perception | 1 | 2006 | 1 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 23 | 0.060 |
Why?
|
| Prognosis | 5 | 2007 | 220 | 0.060 |
Why?
|
| Remission, Spontaneous | 1 | 2006 | 1 | 0.060 |
Why?
|
| Organ Transplantation | 1 | 2006 | 5 | 0.060 |
Why?
|
| Conjunctival Neoplasms | 5 | 1989 | 5 | 0.060 |
Why?
|
| Blood Flow Velocity | 2 | 2006 | 11 | 0.060 |
Why?
|
| Extraoral Traction Appliances | 1 | 1986 | 1 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2026 | 4 | 0.060 |
Why?
|
| Intraoperative Complications | 3 | 2010 | 8 | 0.060 |
Why?
|
| Leucovorin | 2 | 2015 | 3 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2006 | 34 | 0.060 |
Why?
|
| Ciprofloxacin | 3 | 1994 | 4 | 0.060 |
Why?
|
| Eye Infections, Parasitic | 2 | 1998 | 2 | 0.060 |
Why?
|
| Isoxazoles | 1 | 2025 | 1 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2004 | 17 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 82 | 0.060 |
Why?
|
| Medicare | 1 | 2006 | 57 | 0.060 |
Why?
|
| Endemic Diseases | 2 | 2015 | 3 | 0.060 |
Why?
|
| Corneal Opacity | 1 | 2005 | 1 | 0.060 |
Why?
|
| Descemet Membrane | 1 | 2005 | 1 | 0.060 |
Why?
|
| Rabbits | 8 | 2004 | 48 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2002 | 67 | 0.060 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2006 | 76 | 0.060 |
Why?
|
| Alleles | 1 | 2004 | 22 | 0.060 |
Why?
|
| Crotalus | 1 | 2004 | 4 | 0.060 |
Why?
|
| Crotalid Venoms | 1 | 2004 | 6 | 0.060 |
Why?
|
| Snake Bites | 1 | 2004 | 9 | 0.060 |
Why?
|
| Antivenins | 1 | 2004 | 9 | 0.060 |
Why?
|
| Leukocyte Count | 2 | 2001 | 10 | 0.060 |
Why?
|
| DNA Fingerprinting | 1 | 2004 | 1 | 0.060 |
Why?
|
| Azithromycin | 1 | 2004 | 4 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 64 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 153 | 0.050 |
Why?
|
| Capillaries | 3 | 2001 | 11 | 0.050 |
Why?
|
| Blepharitis | 1 | 2004 | 1 | 0.050 |
Why?
|
| Conjunctivitis, Viral | 1 | 2004 | 1 | 0.050 |
Why?
|
| Smallpox Vaccine | 1 | 2004 | 1 | 0.050 |
Why?
|
| Vaccinia | 1 | 2004 | 1 | 0.050 |
Why?
|
| Disease Transmission, Infectious | 1 | 2004 | 7 | 0.050 |
Why?
|
| Developing Countries | 2 | 2014 | 38 | 0.050 |
Why?
|
| Periodicals as Topic | 2 | 2003 | 12 | 0.050 |
Why?
|
| Calcineurin Inhibitors | 1 | 2023 | 1 | 0.050 |
Why?
|
| Alkylating Agents | 1 | 2023 | 7 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2023 | 7 | 0.050 |
Why?
|
| Vision, Ocular | 2 | 2017 | 7 | 0.050 |
Why?
|
| Homosexuality | 2 | 1984 | 6 | 0.050 |
Why?
|
| Mycoses | 2 | 1996 | 5 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2003 | 6 | 0.050 |
Why?
|
| Genetic Linkage | 1 | 2003 | 4 | 0.050 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2003 | 2 | 0.050 |
Why?
|
| Dermatitis, Atopic | 1 | 2003 | 5 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 25 | 0.050 |
Why?
|
| Ophthalmic Solutions | 6 | 2004 | 18 | 0.050 |
Why?
|
| Pathology | 1 | 2002 | 3 | 0.050 |
Why?
|
| Anniversaries and Special Events | 1 | 2002 | 3 | 0.050 |
Why?
|
| Ocular Hypertension | 2 | 2008 | 24 | 0.050 |
Why?
|
| Liver Transplantation | 2 | 2001 | 8 | 0.050 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1982 | 2 | 0.050 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2001 | 2 | 0.050 |
Why?
|
| Hyperopia | 1 | 2001 | 3 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2001 | 11 | 0.050 |
Why?
|
| Vision, Entoptic | 1 | 2001 | 1 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2001 | 10 | 0.040 |
Why?
|
| Fluorophotometry | 1 | 2001 | 4 | 0.040 |
Why?
|
| Chi-Square Distribution | 3 | 1990 | 42 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 70 | 0.040 |
Why?
|
| Rheumatic Diseases | 1 | 2001 | 1 | 0.040 |
Why?
|
| Herpes Genitalis | 1 | 2001 | 2 | 0.040 |
Why?
|
| Herpesvirus 2, Human | 1 | 2001 | 3 | 0.040 |
Why?
|
| Cell Count | 2 | 2016 | 18 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2001 | 31 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2001 | 1 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2001 | 3 | 0.040 |
Why?
|
| Referral and Consultation | 2 | 2018 | 61 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 6 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2020 | 8 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2015 | 8 | 0.040 |
Why?
|
| Logistic Models | 2 | 2014 | 165 | 0.040 |
Why?
|
| Cell Movement | 1 | 2000 | 38 | 0.040 |
Why?
|
| Functional Laterality | 1 | 2020 | 2 | 0.040 |
Why?
|
| Ophthalmologists | 1 | 2020 | 3 | 0.040 |
Why?
|
| Eukaryota | 1 | 2000 | 1 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 8 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 14 | 0.040 |
Why?
|
| Methylprednisolone | 2 | 2006 | 3 | 0.040 |
Why?
|
| Forecasting | 1 | 2000 | 19 | 0.040 |
Why?
|
| Neutropenia | 3 | 1994 | 4 | 0.040 |
Why?
|
| Dissection | 1 | 1999 | 2 | 0.040 |
Why?
|
| Eye Hemorrhage | 2 | 2005 | 2 | 0.040 |
Why?
|
| Random Allocation | 4 | 1995 | 27 | 0.040 |
Why?
|
| Adenoviridae Infections | 1 | 1979 | 1 | 0.040 |
Why?
|
| Adenovirus Infections, Human | 1 | 1979 | 1 | 0.040 |
Why?
|
| Spores | 1 | 1999 | 1 | 0.040 |
Why?
|
| Capillary Permeability | 1 | 1999 | 3 | 0.040 |
Why?
|
| Vasculitis | 1 | 1999 | 3 | 0.040 |
Why?
|
| Keratoconjunctivitis | 1 | 1979 | 2 | 0.040 |
Why?
|
| Cicatrix | 1 | 1999 | 4 | 0.040 |
Why?
|
| Respiration | 1 | 1999 | 13 | 0.040 |
Why?
|
| Hyaluronic Acid | 1 | 1999 | 13 | 0.040 |
Why?
|
| Uveal Diseases | 2 | 1993 | 3 | 0.040 |
Why?
|
| Iris Diseases | 1 | 1999 | 3 | 0.040 |
Why?
|
| Vascular Diseases | 2 | 1990 | 10 | 0.040 |
Why?
|
| Tissue Adhesions | 1 | 1999 | 4 | 0.040 |
Why?
|
| Administration, Ophthalmic | 1 | 2019 | 1 | 0.040 |
Why?
|
| Eyelid Neoplasms | 2 | 1989 | 2 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2019 | 13 | 0.040 |
Why?
|
| Consensus | 1 | 2019 | 39 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2019 | 16 | 0.040 |
Why?
|
| Ocular Hypotension | 1 | 1999 | 3 | 0.040 |
Why?
|
| Fibrinogen | 3 | 2006 | 4 | 0.040 |
Why?
|
| Cysts | 2 | 1997 | 6 | 0.040 |
Why?
|
| Bacterial Infections | 3 | 1989 | 12 | 0.040 |
Why?
|
| Epithelium, Corneal | 1 | 1998 | 5 | 0.040 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 1998 | 2 | 0.040 |
Why?
|
| Delusions | 1 | 1998 | 1 | 0.040 |
Why?
|
| Colitis, Ulcerative | 1 | 1998 | 5 | 0.040 |
Why?
|
| Microcirculation | 2 | 2006 | 14 | 0.030 |
Why?
|
| Orbital Diseases | 2 | 1996 | 2 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 1998 | 84 | 0.030 |
Why?
|
| Ceftazidime | 1 | 1997 | 1 | 0.030 |
Why?
|
| Aminoglycosides | 1 | 1997 | 2 | 0.030 |
Why?
|
| Scleritis | 1 | 1997 | 2 | 0.030 |
Why?
|
| Cephalosporins | 1 | 1997 | 4 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 1997 | 2 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 1996 | 1 | 0.030 |
Why?
|
| Mucormycosis | 1 | 1996 | 1 | 0.030 |
Why?
|
| Optic Chiasm | 1 | 1996 | 1 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2016 | 5 | 0.030 |
Why?
|
| Knee Prosthesis | 1 | 1996 | 1 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 1996 | 2 | 0.030 |
Why?
|
| Blood Sedimentation | 2 | 2006 | 2 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 2016 | 3 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 9 | 0.030 |
Why?
|
| Thrombosis | 1 | 1996 | 13 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 9 | 0.030 |
Why?
|
| Conjunctivitis | 2 | 1989 | 2 | 0.030 |
Why?
|
| Mycobacterium avium Complex | 1 | 1996 | 1 | 0.030 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 1996 | 1 | 0.030 |
Why?
|
| Fusarium | 1 | 1996 | 2 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 1996 | 41 | 0.030 |
Why?
|
| S100 Proteins | 2 | 1988 | 2 | 0.030 |
Why?
|
| Catheters, Indwelling | 1 | 1996 | 6 | 0.030 |
Why?
|
| Corneal Pachymetry | 1 | 2016 | 1 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 1996 | 11 | 0.030 |
Why?
|
| Bacteremia | 1 | 1996 | 8 | 0.030 |
Why?
|
| Filtering Surgery | 1 | 2016 | 6 | 0.030 |
Why?
|
| Amikacin | 2 | 1993 | 3 | 0.030 |
Why?
|
| Data Collection | 1 | 1996 | 38 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 71 | 0.030 |
Why?
|
| Antidotes | 1 | 1996 | 1 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 1995 | 8 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 1995 | 12 | 0.030 |
Why?
|
| HLA-DR1 Antigen | 1 | 1995 | 1 | 0.030 |
Why?
|
| Fascia | 1 | 1995 | 3 | 0.030 |
Why?
|
| Orbit | 1 | 1995 | 6 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 282 | 0.030 |
Why?
|
| Folic Acid Antagonists | 1 | 2015 | 3 | 0.030 |
Why?
|
| Water Supply | 1 | 2015 | 6 | 0.030 |
Why?
|
| Viral Load | 1 | 2015 | 26 | 0.030 |
Why?
|
| Rats | 1 | 2016 | 571 | 0.030 |
Why?
|
| Health Resources | 1 | 2014 | 12 | 0.030 |
Why?
|
| Vaccination | 2 | 2005 | 49 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 111 | 0.030 |
Why?
|
| Microscopy, Electron | 3 | 1991 | 21 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 1994 | 2 | 0.030 |
Why?
|
| Episode of Care | 1 | 2014 | 1 | 0.030 |
Why?
|
| Netherlands | 1 | 2014 | 2 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1994 | 5 | 0.030 |
Why?
|
| Nervous System Diseases | 2 | 1998 | 7 | 0.030 |
Why?
|
| Antitubercular Agents | 1 | 1993 | 4 | 0.030 |
Why?
|
| Asia | 1 | 2013 | 3 | 0.030 |
Why?
|
| Africa | 1 | 2013 | 12 | 0.030 |
Why?
|
| Iontophoresis | 1 | 1993 | 1 | 0.030 |
Why?
|
| Myopia | 1 | 1993 | 4 | 0.020 |
Why?
|
| Survival Analysis | 2 | 1991 | 95 | 0.020 |
Why?
|
| Receptors, Cholinergic | 1 | 2012 | 3 | 0.020 |
Why?
|
| Hyphema | 1 | 1992 | 1 | 0.020 |
Why?
|
| Contraindications | 1 | 1992 | 3 | 0.020 |
Why?
|
| Eye Movements | 1 | 2012 | 7 | 0.020 |
Why?
|
| Oculomotor Muscles | 1 | 2012 | 9 | 0.020 |
Why?
|
| Diplopia | 1 | 2012 | 4 | 0.020 |
Why?
|
| Electromyography | 1 | 2012 | 20 | 0.020 |
Why?
|
| Cholesterol | 2 | 2005 | 37 | 0.020 |
Why?
|
| Epithelium | 2 | 1995 | 22 | 0.020 |
Why?
|
| Triglycerides | 2 | 2005 | 58 | 0.020 |
Why?
|
| Disease Models, Animal | 4 | 1994 | 231 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 2012 | 1 | 0.020 |
Why?
|
| Fungi | 1 | 2012 | 4 | 0.020 |
Why?
|
| Bacteria | 1 | 2012 | 9 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 36 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 23 | 0.020 |
Why?
|
| Venules | 1 | 2011 | 2 | 0.020 |
Why?
|
| Otitis | 1 | 2011 | 1 | 0.020 |
Why?
|
| Arterioles | 1 | 2011 | 8 | 0.020 |
Why?
|
| Sepsis | 1 | 2011 | 6 | 0.020 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1991 | 2 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2011 | 9 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 44 | 0.020 |
Why?
|
| Atovaquone | 1 | 2011 | 1 | 0.020 |
Why?
|
| Scleral Buckling | 1 | 1991 | 1 | 0.020 |
Why?
|
| Simplexvirus | 2 | 1989 | 2 | 0.020 |
Why?
|
| Serotyping | 1 | 2010 | 3 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1990 | 21 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 1990 | 8 | 0.020 |
Why?
|
| Species Specificity | 1 | 2010 | 17 | 0.020 |
Why?
|
| Biological Availability | 2 | 2004 | 8 | 0.020 |
Why?
|
| Blood Viscosity | 2 | 2006 | 6 | 0.020 |
Why?
|
| Corneal Edema | 1 | 2010 | 3 | 0.020 |
Why?
|
| Prosthesis Implantation | 1 | 2010 | 15 | 0.020 |
Why?
|
| DNA, Protozoan | 1 | 2010 | 1 | 0.020 |
Why?
|
| Graft Survival | 1 | 2010 | 36 | 0.020 |
Why?
|
| Acute Disease | 2 | 2006 | 91 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2004 | 18 | 0.020 |
Why?
|
| HLA-B15 Antigen | 1 | 1989 | 1 | 0.020 |
Why?
|
| HLA-B Antigens | 1 | 1989 | 2 | 0.020 |
Why?
|
| Reference Values | 1 | 1989 | 56 | 0.020 |
Why?
|
| Keratosis | 1 | 1989 | 1 | 0.020 |
Why?
|
| Phenotype | 1 | 1989 | 91 | 0.020 |
Why?
|
| Creatinine | 2 | 2000 | 48 | 0.020 |
Why?
|
| Trifluridine | 2 | 2004 | 2 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1988 | 57 | 0.020 |
Why?
|
| Phosphonoacetic Acid | 1 | 1988 | 1 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1988 | 4 | 0.020 |
Why?
|
| Mycobacterium Infections | 1 | 1988 | 1 | 0.020 |
Why?
|
| alpha-Crystallin A Chain | 1 | 2008 | 1 | 0.020 |
Why?
|
| alpha-Crystallin B Chain | 1 | 2008 | 1 | 0.020 |
Why?
|
| beta-Crystallin B Chain | 1 | 2008 | 1 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 1988 | 8 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 16 | 0.020 |
Why?
|
| Lymphoid Tissue | 1 | 1988 | 3 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2008 | 1 | 0.020 |
Why?
|
| Haplotypes | 1 | 2008 | 3 | 0.020 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2008 | 1 | 0.020 |
Why?
|
| France | 1 | 2008 | 2 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 18 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 70 | 0.020 |
Why?
|
| Base Sequence | 1 | 2008 | 65 | 0.020 |
Why?
|
| Ultrasonography | 2 | 1999 | 38 | 0.020 |
Why?
|
| Contact Lenses, Hydrophilic | 1 | 1987 | 2 | 0.020 |
Why?
|
| Eyelids | 1 | 2007 | 2 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 1987 | 6 | 0.020 |
Why?
|
| Nevus | 1 | 1967 | 1 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1986 | 2 | 0.020 |
Why?
|
| Atrophy | 1 | 2006 | 7 | 0.020 |
Why?
|
| Erythrocyte Count | 1 | 2006 | 3 | 0.020 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2006 | 5 | 0.020 |
Why?
|
| Vision Tests | 1 | 2006 | 2 | 0.020 |
Why?
|
| Glaucoma, Neovascular | 1 | 2006 | 7 | 0.020 |
Why?
|
| Tooth Movement Techniques | 1 | 1986 | 1 | 0.020 |
Why?
|
| Gonioscopy | 1 | 2006 | 6 | 0.020 |
Why?
|
| Laser Therapy | 1 | 2006 | 16 | 0.020 |
Why?
|
| Chickenpox Vaccine | 1 | 2005 | 1 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 104 | 0.010 |
Why?
|
| Deltaretrovirus | 1 | 1985 | 1 | 0.010 |
Why?
|
| Trabeculectomy | 1 | 2006 | 40 | 0.010 |
Why?
|
| Tissue Donors | 1 | 1985 | 14 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2006 | 39 | 0.010 |
Why?
|
| Sclera | 2 | 1997 | 7 | 0.010 |
Why?
|
| Aging | 1 | 2006 | 105 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2005 | 16 | 0.010 |
Why?
|
| Colombia | 1 | 2004 | 1 | 0.010 |
Why?
|
| Ecuador | 1 | 2004 | 1 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 22 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 27 | 0.010 |
Why?
|
| Models, Animal | 1 | 2004 | 23 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2004 | 1 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 2004 | 2 | 0.010 |
Why?
|
| Colony Count, Microbial | 2 | 1994 | 3 | 0.010 |
Why?
|
| Military Personnel | 1 | 2004 | 5 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1983 | 25 | 0.010 |
Why?
|
| Ointments | 1 | 2003 | 1 | 0.010 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2003 | 2 | 0.010 |
Why?
|
| Optic Nerve | 2 | 1996 | 12 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2002 | 11 | 0.010 |
Why?
|
| Candidiasis, Chronic Mucocutaneous | 1 | 1982 | 1 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1982 | 5 | 0.010 |
Why?
|
| Etanercept | 1 | 2001 | 1 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2001 | 4 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 2001 | 4 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2001 | 14 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2001 | 48 | 0.010 |
Why?
|
| Virus Cultivation | 1 | 2000 | 1 | 0.010 |
Why?
|
| Cytokines | 1 | 2001 | 80 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2000 | 6 | 0.010 |
Why?
|
| Hemorheology | 1 | 2000 | 1 | 0.010 |
Why?
|
| Filtration | 1 | 2000 | 2 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2000 | 23 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2000 | 66 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 1979 | 1 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2000 | 112 | 0.010 |
Why?
|
| Arabinofuranosyluracil | 1 | 1998 | 1 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 1998 | 1 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1998 | 5 | 0.010 |
Why?
|
| Ectoparasitic Infestations | 1 | 1998 | 1 | 0.010 |
Why?
|
| Self Mutilation | 1 | 1998 | 1 | 0.010 |
Why?
|
| Self-Injurious Behavior | 1 | 1998 | 8 | 0.010 |
Why?
|
| Probenecid | 1 | 1998 | 1 | 0.010 |
Why?
|
| Renal Agents | 1 | 1998 | 4 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1998 | 9 | 0.010 |
Why?
|
| Proteinuria | 1 | 1998 | 15 | 0.010 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1997 | 2 | 0.010 |
Why?
|
| Paranasal Sinus Diseases | 1 | 1996 | 1 | 0.010 |
Why?
|
| Rhizopus | 1 | 1996 | 1 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1996 | 8 | 0.010 |
Why?
|
| Hip Prosthesis | 1 | 1996 | 4 | 0.010 |
Why?
|
| Fungemia | 1 | 1996 | 1 | 0.010 |
Why?
|
| Fluconazole | 1 | 1996 | 3 | 0.010 |
Why?
|
| Amphotericin B | 1 | 1996 | 4 | 0.010 |
Why?
|
| Antifungal Agents | 1 | 1996 | 9 | 0.010 |
Why?
|
| Kidney | 1 | 1998 | 184 | 0.010 |
Why?
|
| Hospitals, University | 1 | 1996 | 4 | 0.010 |
Why?
|
| Family Practice | 1 | 1996 | 21 | 0.010 |
Why?
|
| Community Health Services | 1 | 1996 | 35 | 0.010 |
Why?
|
| Central America | 1 | 1995 | 1 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1995 | 4 | 0.010 |
Why?
|
| Mexico | 1 | 1995 | 8 | 0.010 |
Why?
|
| Absorption | 1 | 1995 | 5 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1994 | 12 | 0.010 |
Why?
|
| Vancomycin | 1 | 1993 | 5 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1994 | 50 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1994 | 27 | 0.010 |
Why?
|
| Half-Life | 1 | 1993 | 4 | 0.010 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 1992 | 1 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 1991 | 2 | 0.010 |
Why?
|
| Cryosurgery | 1 | 1991 | 1 | 0.010 |
Why?
|
| Light Coagulation | 1 | 1991 | 2 | 0.010 |
Why?
|
| Herpes Simplex | 1 | 1991 | 3 | 0.010 |
Why?
|
| Amebicides | 1 | 1990 | 1 | 0.010 |
Why?
|
| Rheology | 1 | 1990 | 1 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1990 | 63 | 0.000 |
Why?
|
| Algorithms | 1 | 1990 | 83 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1990 | 34 | 0.000 |
Why?
|
| Fixatives | 1 | 1989 | 1 | 0.000 |
Why?
|
| Keratins | 1 | 1989 | 11 | 0.000 |
Why?
|
| Erythema | 1 | 1989 | 1 | 0.000 |
Why?
|
| Radiotherapy | 1 | 1989 | 4 | 0.000 |
Why?
|
| Remission Induction | 1 | 1989 | 5 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1989 | 23 | 0.000 |
Why?
|
| Epithelial Cells | 1 | 1989 | 49 | 0.000 |
Why?
|
| Radiation Injuries | 1 | 1989 | 9 | 0.000 |
Why?
|
| Palliative Care | 1 | 1989 | 22 | 0.000 |
Why?
|
| Choroid Neoplasms | 1 | 1988 | 1 | 0.000 |
Why?
|
| Eye Foreign Bodies | 1 | 1988 | 2 | 0.000 |
Why?
|
| Contact Lenses | 1 | 1988 | 3 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1988 | 118 | 0.000 |
Why?
|
| Neurilemmoma | 1 | 1967 | 1 | 0.000 |
Why?
|
| Xanthogranuloma, Juvenile | 1 | 1967 | 1 | 0.000 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1967 | 3 | 0.000 |
Why?
|
| Hemangioma | 1 | 1967 | 3 | 0.000 |
Why?
|
| Denervation | 1 | 1987 | 9 | 0.000 |
Why?
|
| Kidney Transplantation | 1 | 1988 | 101 | 0.000 |
Why?
|
| Leiomyoma | 1 | 1967 | 33 | 0.000 |
Why?
|
| Immune Complex Diseases | 1 | 1985 | 1 | 0.000 |
Why?
|
| Virus Diseases | 1 | 1985 | 3 | 0.000 |
Why?
|
| Lymphatic Diseases | 1 | 1984 | 4 | 0.000 |
Why?
|
| Retinoblastoma | 1 | 1983 | 3 | 0.000 |
Why?
|